Pierre Fabre Labs expands R&D portfolio; announces acquisition of the worldwide rights for PFL-721 & PFL-241: Castres, France Wednesday, June 18, 2025, 11:00 Hrs [IST] Pierre Fabr ...

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, ...

Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

J&J’s Janssen unit is seeking approval of the drug in a specific patient group – those with exon 20 insertion mutations whose disease has progressed despite first-line chemotherapy.

"As patients living with EGFR exon 20 insertion-mutated NSCLC face a particularly poor prognosis, the need for innovative combinations in the frontline setting is vital." EGFR mutations are the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A local football match in Melbourne’s east was stopped for almost an hour on Saturday following a sickening on-field ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...